Neumora

Today, neuropsychiatric disorders and neurodegenerative diseases are classified as broad disorders defined by clinical symptoms, leading to “one-size-fits-all” treatment approaches. In drug development, this has led to patient heterogeneity, subjective trial endpoints, and a lower likelihood of success. 

Through our proprietary precision data science platform, we aim to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics and increase the probability of developing effective medicines. Our platform integrates multiple types of data to create Data Biopsy Signatures™ and Precision Phenotypes™ to map disease drivers to the defined patient subtypes.